CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced best efforts public offering of 15,000,000 shares of its common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock ("Pre-funded Warrants")and w ...